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Abstract
Background: Cyclin D1 plays a major role as a potential contributor to the multistep process of
oncogenesis; nevertheless its prognostic significance in colon cancer has already been examined in
a few studies and needs to be further delineated. The aim of this study was to assess the expression
of cyclin D1 and pRb and to correlate them with tumor histological stage and grade, proliferative
capacity (Ki-67 labeling index) and clinical parameters, in order to delineate their impact on
prognosis.
Methods: One hundred and eleven patients, who underwent surgical resection of the colon for
colon cancer constituted the group of our study. The immunohistochemical expression of cyclin
D1, Rb and Ki-67 proteins was examined and correlated with clinico-pathological parameters and
survival.
Results: The 5-years survival rate of patients presenting cyclin D1 positive tumors was 54%, while
that of cyclin D1 negative ones was 67% (P = > 0.05). The survival rate of patients with pRb positive
tumors was similar to that of pRb negatine ones. Significant association was observed between Ki-
67 and cyclin D1 positivity (P = 0.045). Univariate analysis revealed worse survival in advanced stage
patients presenting cyclin D1 positive tumors (P = 0.025). Additionally, the survival of patients aging
less than 70 years old was correlated to cyclin D1 positivity (P = 0.009). Multivariate survival
analysis revealed statistical significance for stage and hepatic metastasis.
Conclusion: Even though cyclin D1 and pRb have not disclosed any clear association with shorter
survival, cyclin D1 positivity may be a useful predictor of subgroup patients with colon cancer being
in advanced stage and early age.
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Background
In colon cancer patients, histological stage has been con-
sidered as the most important predictor of recurrence.
However, for better management of patients, especially
those within the same stage, additional factors should be
examined. The product of the retinoblastoma gene (pRb)
is the master regulator of entry into the cell- cycle in nor-
mal cells being deregulated in almost all tumors [1,2]. The
pRb activity is regulated by D-type cyclins and can be
downmodulated by kinase inhibitors. The discovery of
cyclins and their associated catalytic subunits, the cyclin
dependent kinases (cdks), as key regulators of the cell-
cycle progression, opened up a new debate on their possi-
ble involvement in tumorigenesis [1-3]. Recently has been
demonstrated that cyclin D1 acts as an oncogene in vitro
and in vivo [4]. Once cells have entered the cell-cycle they
are normally committed to go on and divide, hence the so
called G1 cyclins have a predominant role in pushing cells
toward progression. The cyclin D1/cdk4, cyclin D1/cdk6
and cyclin E/cdk2 complexes are the main regulators of
the G1→S transition, each of them controlling a different
and discrete rate limited step [2,5,6]. Among these, cyclin
D1 presents the strongest evidence of a potential contribu-
tion to the multistep process of oncogenesis [7]. However,
limited number of studies have examined the association
of cyclin D1 expression and prognosis of patients with dif-
ferent malignant tumors [8-12], while others have evalu-
ated it in colon adenocarcinoma with equivocal results
[13-16]. According to the previously published studies the
role of cyclin D1 remains controversial with studies to
report both positive and negative prognostic values since
the role of cyclin D1 is complex and multiple.
In the present study, cyclin D1 and pRb expression was
assessed immunohistochemically in tumoral tissues
obtained from colon adenocarcinoma patients. Cyclin D1
and pRb immunohistochemical data were correlated with
tumor histological stage and grade, proliferative capacity
(Ki-67 labeling index), and clinical parameters, in order to
delineate their impact on prognosis.
Patients and methods
Patients
One hundred and eleven consecutive patients, who
underwent colonic surgical resection due to colon cancer
constituted the group of our study (age range, 42–94;
mean 70.6 years). Patients with unresectable colon cancer
were excluded. Rectal cancer was also excluded from our
study as most reports suggest that the survival of rectal
cancer patients is poorer than that observed in colon can-
cer ones. Additionally, survival rate diminishes as rectal
tumors are located more distally in the bowel. Sixty six of
the patients were men (59.4%) and 45 (40.6%) were
women. No patient received chemotherapy or radiation
therapy before surgery. Surgical treatment was curative in
all patients. Adjuvant chemotherapy was given in patients
when the serosa was infiltrated by the tumor. Tumors
were located in the cecum and the ascending colon in 31
cases (27.9%), in the transverse in 7 (6.3%), in the
descending colon in 11 (9.9%) and in the sigmoid in 62
ones (55.9%). The resected tumors were histologically
staged according to Dukes classification as: A, 16 cases
(14.4%); B, 44 (39.6%); C, 26 (23.4%); and D, 25
(22.5%). Three levels of differentiation were used to clas-
sify grading as: well differentiated, 8 cases (7.2%); moder-
ately, 83 (74.8%); and poorly, 20 (18%). The patients
were followed for a time interval of 2 up to 68 months,
mean 38.3 ± 16.7 months, median 38 months. Patients
who were died during two months after surgery were
excluded from the study, avoiding with this way deaths
due to postoperative complications.
Immunohistochemistry
A mouse (IgG1 k) monoclonal antibody that reacts with
human cyclin D1 (Santa Cruz Biochemicals, Santa Cruz,
Calif., USA), a rabbit polyclonal one that reacts with
human pRb (Santa Cruz Biochemicals), and another
mouse (IgG1 k) monoclonal antibody (MIB-1) that reacts
with Ki-67 antigen (Dakopatts, Glostrup, Denmark) were
used in this study. Formalin-fixed paraffin-embedded tis-
sue sections of 5 µm thickness were dewaxed in xylene
and were brought to water through graded alcohols. Anti-
gen retrieval was performed for Ki-67 antigen detection
only, by microwaving slides in 10 mM citrate buffer (pH
6.0) for 15 min at high power, according to the manufac-
turer's instructions. To remove the endogenous peroxi-
dase activity, sections were treated with freshly prepared
0.3% (vol/vol) hydrogen peroxide in methanol in dark,
for 30 min, at room temperature (RT). Non-specific anti-
body binding was then blocked with a ready to use block-
ing reagent (Snipper, Biocare Biochemicals, Walnut
Creek, CA, USA), for 10 min. The sections were then incu-
bated for 1 h, at RT, with the primary antibodies diluted
1:100 in phosphate buffered saline (PBS). After washing
three times with PBS, sections were incubated for 20 min
at RT with linking biotinylated reagent, rabbit anti-mouse
immunoglobulins (Dakopatts) for cyclin D1 and Ki-67
detection, and swine, anti-rabbit immunoglobulins for
pRb one, both diluted 1:200 in PBS. The slides were then
rinsed three times with PBS followed by incubation with
peroxidase-conjugated streptavidin label (AB Complex,
Dakopatts) for 20 min, at RT. Peroxidase activity was
developed in 0.5% (vol/vol) 3,3'-diaminobenzidine
hydrochloride (DAB, Sigma, Saint Louis, MO, USA) in
PBS containing 0.03% (vol/vol) hydrogen peroxide for 2
min. Sections were counterstained with Harris' hematoxy-
lin and mounted in gelatin (Sigma).
The stained sections were independently assessed by two
different observers and specimens were considered "posi-World Journal of Surgical Oncology 2006, 4:5 http://www.wjso.com/content/4/1/5
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tive either for cyclin D1 or pRb" when more than 5% of
tumor cells within the section were positively stained. Five
percent was used as the cutoff value as referred in other
studies [13,15,17]. The pattern of cyclin D1 and pRb
immunostaining in positive cases was characterized either
as nuclear only, or cytoplasmic and nuclear or cytoplas-
mic only. The intensity of cyclin D1 immunostaining in
tumor cells was also semiquantitatively assessed as low
(+), moderate (++), or high (+++). Control slides included
in each experiment consisted of specific tissues previously
shown to express the antigen of interest as positive con-
trols (i.e. tonsil for cyclin D1 and pRb; normal colon for
Ki-67). Internal experimental negative controls were also
included by omission of the primary antibody. The frac-
tion of Ki-67 positive cells was evaluated using a four
graded scale of 0–5%, 6–25%, 26–50%, and >50%.
Intraobserver discrepancies (<10%) were restained and
reevaluated, and agreement was reached.
Statistical Analysis
Statistical analysis was performed using the statistical
package SPSS version 10.00. The correlation between cyc-
lin D1, pRb and Ki-67 expression and various clinico-
pathological variables (age, location, stage and grade,
lymph node and liver metastasis and venous invasion)
was assessed using the chi-square test. The Mann-Whitney
U test was also applied in order to compare the correlation
between Cyclin D1, pRB and Ki-67 expression in the
colon cancer cases of our study. Survival curves were con-
structed using the Kaplan-Meier method and compared
using the log rank test. The influence of each potential
prognostic factor on the patients' survival was evaluated
using Cox regression analysis. Results were considered sta-
tistically significant when P-value was less than 0.05.
Results
Clinico-pathological characteristics of patients and tissue
samples are summarized in Table 1. Positive cyclin D1
immunostaining was observed in 71 out of 111 patients
(63.9%). The pattern of cyclin D1 staining was nuclear
only in 16 out of 71 tumors (22.5%), cytoplasmic only in
3 out of 71 (4.2%) and cytoplasmic and nuclear in 52 out
of 71 ones (73.2%). The intensity of cyclin D1 immunos-
taining was assessed as low in 34 out of 71 cases (47.9%),
moderate in 26 out of 71 (36.6%), and high in 11 out of
71 ones (15.5%). There was no statistically significant
association between cyclin D1 expression and clinico-
pathological variables, as age, tumor location, histological
stage or grade, lymph node or hepatic metastasis, and ves-
sel invasion (Table 1). The pattern and intensity of cyclin
D1 immunostaining was also not significantly associated
with any tumor or patient characteristics (unpublished
data).
Seventy one patients presented positive staining for pRb
did not show any statistical significant association with
clinico-pathological variables, as age, tumor location, his-
tologic grade and stage, lymph node or hepatic metastasis,
Table 1: Cyclin D1 and pRb expression in relation to different clinico-pathological characteristics (X2)
Variable No of cases Cyclin D1 expression P value pRb expression P value
Negative Positive Negative Positive
Age
<70 52 15 37 0,139 18 34 0.770
> 7 0 5 92 53 4 2 23 7
Dukes' stage
A and B 60 22 38 0,881 22 38 0.881




91 36 55 0,099 30 61 0.151
P o o r 2 041 6 1 0 1 0
Tumor location
Proximal 38 12 26 0,480 17 21 0.168
Distal 73 28 45 23 50
Lymph node 
metastas
Negative 68 22 45 0,541 23 45 0.541
Positive 43 17 26 17 26
Liver metastasis
Negative 93 36 57 0,182 34 59 0.794
P o s i t i v e 1 841 4 61 2
Venous invasion
Negative 83 31 52 0,620 28 55 0.385
P o s i t i v e 2 891 9 1 2 1 6World Journal of Surgical Oncology 2006, 4:5 http://www.wjso.com/content/4/1/5
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and vessel invasion (Table 1). The only pattern of immu-
nostaining observed in pRb positive cases was the nuclear
one. The intensity of pRb staining was assessed as low in
30 out of 71 cases (42.2%), as moderate in 20 out of 71
(28.2%), and as high in 21 out of 71 (29.6%). The sur-
vival rate of patients with pRb positive tumors was similar
to that of pRb negative ones (data not shown). Among the
40 cases of pRb negative stained tumors, 18 of them were
cyclin D1 negative. pRb expression was not statistically
significantly associated with that of cyclin D1. The pattern
of cyclin D1 immunostaining was not significantly associ-
ated with pRb expression (unpublished data).
To determine the proliferative capacity in colon cancer
cases with abnormal expression of pRb and/or cyclin D1,
the percentage of Ki-67 positive cells was assessed (Table
2). Intraobserver agreement was documented by Kappa
statistics (K value = 0.899), that was statistically signifi-
cant (P = 0.000). Statistically significant association was
observed between tumor proliferative capacity expressed
as Ki-67 labeling index and positive cyclin D1 staining (P
= 0.045), but not with pRb one. Among the 71 tumors
presenting cyclin D1 positivity, 25 assessed to have a frac-
tion of Ki-67 positive cells of 6–25%, 12 have 26–50%,
and 30 have >50%. Among the 71 patients presenting pRb
positive tumors, 39 assessed to have a fraction of Ki-67
positive cells of >50%, 14 have 26–50%, and 21 have 6–
25% (P = 0.217, Table 2).
The 5-years survival rate of patients with cyclin D1 posi-
tive tumors was 54%, while that of patients with cyclin D1
negative ones was 67%. Even though the survival of
Kaplan-Meier survival curves for 52 patients <70 years old  according to cyclin D1 protein expression [protein positive  (solid line), n = 37; protein negative (dotted line), n = 15; P =  0.009 by the log rank test] Figure 2
Kaplan-Meier survival curves for 52 patients <70 years old 
according to cyclin D1 protein expression [protein positive 
(solid line), n = 37; protein negative (dotted line), n = 15; P = 
0.009 by the log rank test].
Kaplan-Meier survival curves for 51 patients in stages C and  D according to cyclin D1 protein expression [protein posi- tive (solid line), n = 33; protein negative (dotted line), n = 18;  P = 0.025 by the log rank test] Figure 1
Kaplan-Meier survival curves for 51 patients in stages C and 
D according to cyclin D1 protein expression [protein posi-
tive (solid line), n = 33; protein negative (dotted line), n = 18; 
P = 0.025 by the log rank test].
Table 2: Immunohistochemical expression of pRb and Ki-67 in relation to cyclin D1 expression.
pRb P value Cyclin D1 P value
pos negative pos negative
Ki-67
0–5% 6 7 0.217 4 9 0.045
6–25% 21 16 25 12
26–50% 14 6 12 8
>50% 30 11 30 11
No of cases 71 40 71 40World Journal of Surgical Oncology 2006, 4:5 http://www.wjso.com/content/4/1/5
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patients with cyclin D1 positive tumors was shorter, the
difference was not statistically significant. The survival of
patients presenting advanced stage (stage C and D) and
cyclin D1 positive tumors was significantly worse than
that of patients with cyclin D1 negative ones (P = 0.025,
figure 1). Additionally, the survival of patients less than
70 years old was significantly correlated to positive cyclin
D1 expression (P = 0.009; figure 2). Multivariate survival
analysis revealed statistical significance for stage and
hepatic metastasis (Table 3).
Discussion
In the present study, the expression of cyclin D1 and pRb
in 111 cases of resected primary human colon carcinomas
was investigated. The frequency of cyclin D1 positivity
revealed in colon carcinoma cases was 63,9%, being sim-
ilar to the results described by Arber et al [14], and higher
than that reported by Palmqvist et al [13]. In other studies,
neither the pattern nor the intensity of cyclin D1 staining
was scored. Differences in the pattern of cyclin D1 stain-
ing were noted in the colon cancer cases examined in our
study. The presence of cytoplasmic pattern could suggest
that not only elevated cyclin D1 levels occurring in colon
cancer tumoral cells but alterations in the transport of the
protein in the nucleus also exist. Due to the variety of
parameters used, (e.g. antibodies, tissue fixation, thresh-
old definitions for positivity or overexpression, semi-
quantitative scales), it is often difficult to make a direct
comparison between the results obtained in different
studies.
We have also reported lack of correlation between cyclin
D1 and pRb positivity and clinico-pathological tumor
characteristics. Positive cyclin D1 and pRb stainings did
not show any specificity to the location of the tumor. Our
results contrast with those of other studies that showed
strong specificity to the right colon [13,18], emphasizing
the possibility that cancers developed in the right colon
have a different spectrum of genetic damage and biologi-
cal behavior than those developed in the left colon and
rectum.
In our study, the proliferate activity (Ki-67 protein expres-
sion) in colon cancer cases was correlated with cyclin D1
levels (P = 0.045, Table 2) suggesting that cyclin D1 con-
tributes to an increased proliferate potential that might be
adequate in colon cancer cases [19]. On the contrary,
opposite results have been reported in breast [20], and
hypopharyngeal [21] cancer. Thus, cyclin D1 might be
important in the mechanisms behind malignancies, and it
confers growth advantage, according to the obvious func-
tion in the G1-S transition.
It has been shown that cyclin D1 expression correlated
with poor survival rate in a variety of human malignancies
[8-10]. Previous studies have proposed a link between cyc-
lin D1 expression and short survival rate in colon cancer
patients [13,15], while this correlation was not observed
in three other published series [14,16,22,23]. In the
present study, only the survival of patients with cyclin D1
positive and advanced tumor stage (stage C and D) was
significantly worse (P = 0.025). Our study also revealed
that the survival rate of patients aged less than 70 years old
presenting cyclin D1 positivity was significantly worse (P
= 0.009), suggesting possibly that environmental effects
are likely to dominate over genetic ones in older patients
Table 3: Cox proportional hazard model for factors associated with survival of colon cancer.
Variable Relative risk 95% CI P value
Dukes' stage
AB vs CD 8.59 2.67–27.56 0.003
Grade
Well+moderate vs. poor 1.29 0.64–2.61 0.471
Site
Proximal vs. distal 1.00 0.52–1.92 0.989
Lymph node metastasis
Negative vs. positive 1.41 0.55–3.62 0.471
Hepatic metastasis
Negative vs. positive 0.12 0.05–0.31 0.000
Vessel invasion
Negative vs. positive 0.81 0.40–1.65 0.569
Adjuvant therapy
Yes vs. No 0.28 0.03–2.23 0.233
pRb
Negative vs. positive 0.83 0.43–1.60 0.580
Cyclin D1
Negative vs positive 1.03 0.50–2.12 0.919
CI = Confidence intervalWorld Journal of Surgical Oncology 2006, 4:5 http://www.wjso.com/content/4/1/5
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[24]. This hypothesis has been reinforced recently by the
study of Lichtenstein et al [25].
In our study of 111 colon cancer cases, the detection of
pRb positivity has not disclosed a clear association with
poor survival (P = 0.444). Regarding cyclin D1 positivity,
our data indicate an association with shorter survival. We
found a very significant correlation between Dukes' stage
and poor clinical survival (P = 0.000). However, as in the
clinical practice, the histological staging and differentia-
tion provide the predominant prognostic information; it
is therefore relevant to evaluate the relative contributions
of cyclin D1 and pRb expression as compared to the clin-
ico-pathological features. This evaluation can be per-
formed by forward analysis in a Cox model [26]. In such
analysis, we did not find any statistical significance, or a
higher relative risk factor of poor prognosis for pRb and
cyclin D1 positivity within the same confidence interval.
Our results are in agreement with those of others [13,27]
who also did not found any significant correlation.
The frequency of pRb positivity was 63.9%, and it was
substantially more frequent than its inactivation. The fre-
quency of pRb expression is in agreement with earlier
observations that approximately one-third of colorectal
cancers have increased copy numbers of one Rb1 allele
[28,29], a 2- to 5- fold increase in Rb protein and mRNA
levels compared with adjacent normal mucosa [30], as
well as a 2-fold increase of the abundance of pRb and its
phosphorylation status compared with normal mucosa
[31]. It is known that the Rb gene is a tumor suppressor
one and it is difficult to explain its overexpression in
colon cancer. Presumably, it cannot be excluded that the
Rb gene might contain genetic abnormalities which could
lead to a functional inactivated protein with a subsequent
longer degradation resulting in high protein levels
[28,32].
In conclusion, our study did not demonstrate an overall
significantly worse prognosis in patients with cyclin D1 or
pRb positivity. However, it showed that the survival rate
of a patients subgroup presenting in advanced stage, or in
patients aged less than 70 years old with cyclin D1 posi-
tive tumors was significantly worse. Consequently, our
study indicates that cyclin D1 expression may be a predic-
tor of patients presenting in advanced stage and of
patients at young age. Thus, the importance of cyclin D1
expression seems to be complex and different between
tumors, and therefore, our study encourage further and
larger studies for cyclin D1 expression in colon cancer, in
order to verify if the expression of this molecule indicates
poor prognosis.
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